CELL WALL BIOGENESIS: TARGET FOR NEW ANTI-TB DRUGS
细胞壁生物发生:新抗结核药物的目标
基本信息
- 批准号:3148759
- 负责人:
- 金额:$ 36.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-09-30 至 1997-08-31
- 项目状态:已结题
- 来源:
- 关键词:Mycobacterium tuberculosis antitubercular agents arabinose carbohydrate biosynthesis cell wall disease /disorder model drug design /synthesis /production drug resistance drug screening /evaluation electroporation enzyme inhibitors enzyme substrate analog ethambutol genetic library isoniazid laboratory mouse microorganism disease chemotherapy microorganism genetics microorganism growth molecular cloning molecular site mutant nonhuman therapy evaluation tuberculosis
项目摘要
The lack of fundamental knowledge of the biochemistry and genetics of
Mycobacterium tuberculosis and the lack of a variety of drugs against
tuberculosis have become serious problems in the face of increased
prevalence and multiple drug resistance. Basic studies on the cell wall
of mycobacteria emerging from this laboratory have revealed the presence
of a unique tetramycolated penta-D-arabinoside (McNeil et al. , J. Biol,
Chem, 266, 13217-13223, 1991). This unit is essential for the structural
integrity and permeability characteristics of the cell wall of M.
tuberculosis and provides a germane target for a new generation of
anti-tuberculosis drugs. Neither mycolic acids nor D-arabinose are
present in the host, and two effective antimycobacterials, isoniazid
(INH) and ethambutol, are known to inhibit the biogenesis of
mycolylarabinoside. In this proposal, we present a synergistic balance
of fundamental biochemical and genetic research coupled with the design,
chemical synthesis, and antimicrobial testing of new enzyme antagonists.
Specifically, we will elucidate the pathway for arabinan biosynthesis,
develop assays for relevant enzymes, and clone the genes for particularly
promising drug targets. To accomplish this, we have developed an active
enzyme system capable of converting ribulose-5-phosphate to
arabinose-5-phosphate and beyond, to cell wall arabinan. In parallel
studies, we will chemically synthesize transition state analogs and
substrate analogs of key enzymes. The effect of these inhibitors on
enzymatic conversions will be determined separately from their effect on
whole bacteria, allowing compounds which inhibit enzymes but are unable
to penetrate the bacteria to be recognized and then chemically modified
to allow for permeation. As warranted, the effects of the new compounds
on bacterial growth in mice will be determined. As well as the new
antagonists, INH and ethambutol will be studied. Preliminary results
have identified the general site of action of ethambutol on arabinan
synthesis; the specific enzymes involved will be identified. In this
regard, genes encoding for resistance to ethambutol have been cloned;
recent evidence suggests that one of the ethambutol-resistance
determinants is involved in arabinan biosynthesis. The cloning of genes
encoding for INH resistance is proposed. In addition, enzymes
susceptible to INH will be identified using an enzyme system capable of
synthesizing mycolic acids from 14C labeled medium chain fatty acids.
Finally, the ability of novel, tailored inhibitors such as
cyclopropene-containing analogs to inhibit mycolic acid synthesis will be
explored.
缺乏生物化学和遗传学的基本知识,
结核分枝杆菌缺乏多种药物防治
结核病已经成为严重的问题,
流行和多重耐药性。 细胞壁的基础研究
实验室发现的分枝杆菌
一种独特的四分枝杆菌化的五-D-阿拉伯糖苷(McNeil等人,J. Biol,
Chem,266,13217-13223,1991)。 该单元对于结构至关重要
的细胞壁的完整性和渗透性特征。
结核病,并提供了一个密切的目标,新一代的
抗结核药物。 分枝菌酸和D-阿拉伯糖都不是
和两种有效的抗分枝杆菌药物异烟肼
(INH)和乙胺丁醇,已知可抑制
分枝石松苷。 在这个建议中,我们提出了一个协同平衡,
基础生物化学和遗传学研究与设计相结合,
新酶拮抗剂的化学合成和抗微生物测试。
具体来说,我们将阐明阿拉伯聚糖生物合成的途径,
开发相关酶的检测方法,并克隆基因,
有希望的药物靶点 为了实现这一目标,我们开发了一种积极的
能够将核酮糖-5-磷酸转化为
阿拉伯糖-5-磷酸和更高,与细胞壁阿拉伯聚糖结合。 并行
研究,我们将化学合成过渡态类似物,
关键酶的底物类似物。 这些抑制剂对
酶促转化将与它们对
整个细菌,允许化合物抑制酶,但不能
穿透细菌进行识别,然后进行化学修饰
以允许渗透。 正如所保证的,新化合物的效果
对小鼠体内细菌生长的影响。 以及新的
拮抗剂,INH和乙胺丁醇将被研究。 初步结果
已确定乙胺丁醇对阿拉伯聚糖的一般作用部位
合成;将鉴定所涉及的特定酶。 在这
在这方面,已经克隆了编码乙胺丁醇抗性的基因;
最近的证据表明,乙胺丁醇耐药性之一
决定簇参与阿拉伯聚糖的生物合成。 基因克隆
编码的INH耐药性的建议。 此外,酶
将使用能够
由14 C标记的中链脂肪酸合成分枝菌酸。
最后,新的、定制的抑制剂,如
抑制分枝菌酸合成的含环丙沙星的类似物将被
探讨了
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael R McNeil其他文献
Michael R McNeil的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael R McNeil', 18)}}的其他基金
HTS Screen of TB RmlC & RmlD dTDP-Rhamnose Formation Enzymes
TB RmlC 的 HTS 筛查
- 批准号:
7363783 - 财政年份:2007
- 资助金额:
$ 36.74万 - 项目类别:
Glucosamine-1-phosphate and serine acetylases: HTS assays and configurations
1-磷酸氨基葡萄糖和丝氨酸乙酰酶:HTS 测定和配置
- 批准号:
7678708 - 财政年份:2006
- 资助金额:
$ 36.74万 - 项目类别:
Glucosamine-1-phosphate and serine acetylases: HTS assays and configurations
1-磷酸氨基葡萄糖和丝氨酸乙酰酶:HTS 测定和配置
- 批准号:
7169481 - 财政年份:2006
- 资助金额:
$ 36.74万 - 项目类别:
MDR-TB Drugs: Targeting Cell Wall Synthetic Enzymes
耐多药结核病药物:靶向细胞壁合成酶
- 批准号:
7071724 - 财政年份:2004
- 资助金额:
$ 36.74万 - 项目类别:
Multi-Drug Resistant Tuberculosis Drugs: Targeting Cell Wall Synthetic Enzymes
多重耐药结核病药物:靶向细胞壁合成酶
- 批准号:
7230940 - 财政年份:2004
- 资助金额:
$ 36.74万 - 项目类别:
MDR-TB Drugs: Targeting Cell Wall Synthetic Enzymes
耐多药结核病药物:靶向细胞壁合成酶
- 批准号:
6710418 - 财政年份:2004
- 资助金额:
$ 36.74万 - 项目类别:
MDR-TB Drugs: Targeting Cell Wall Synthetic Enzymes
耐多药结核病药物:靶向细胞壁合成酶
- 批准号:
6904586 - 财政年份:2004
- 资助金额:
$ 36.74万 - 项目类别:
D-arabinose synthesis in TB using Azorhizobium as a tool
使用固氮根瘤菌作为工具合成结核病中的 D-阿拉伯糖
- 批准号:
6708032 - 财政年份:2003
- 资助金额:
$ 36.74万 - 项目类别:
D-arabinose synthesis in TB using Azorhizobium as a tool
使用固氮根瘤菌作为工具合成结核病中的 D-阿拉伯糖
- 批准号:
6589461 - 财政年份:2003
- 资助金额:
$ 36.74万 - 项目类别:
相似海外基金
Inhalation of antitubercular agents for efficient treatment of tuberculosis
吸入抗结核药物有效治疗结核病
- 批准号:
22300171 - 财政年份:2010
- 资助金额:
$ 36.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Thioesterase Inhibitors of Mycolic Acid Biosynthesis as Antitubercular Agents
作为抗结核药物的分枝菌酸生物合成的硫酯酶抑制剂
- 批准号:
7477115 - 财政年份:2007
- 资助金额:
$ 36.74万 - 项目类别:
Thioesterase Inhibitors of Mycolic Acid Biosynthesis as Antitubercular Agents
作为抗结核药物的分枝菌酸生物合成的硫酯酶抑制剂
- 批准号:
7178639 - 财政年份:2007
- 资助金额:
$ 36.74万 - 项目类别:
Pseudopteroxazole and Related Antitubercular Agents
拟蝶恶唑及相关抗结核药
- 批准号:
6863274 - 财政年份:2004
- 资助金额:
$ 36.74万 - 项目类别:
Pseudopteroxazole and Related Antitubercular Agents
拟蝶恶唑及相关抗结核药
- 批准号:
7151457 - 财政年份:2004
- 资助金额:
$ 36.74万 - 项目类别:
Pseudopteroxazole and Related Antitubercular Agents
拟蝶恶唑及相关抗结核药
- 批准号:
6986743 - 财政年份:2004
- 资助金额:
$ 36.74万 - 项目类别:
ANTITUBERCULAR AGENTS FROM MEDICINAL PLANTS OF NIGERIA
来自尼日利亚药用植物的抗结核药物
- 批准号:
2870418 - 财政年份:1998
- 资助金额:
$ 36.74万 - 项目类别:
NOVEL ANTITUBERCULAR AGENTS VIA COMBINATORIAL CHEMISTRY
通过组合化学的新型抗结核药物
- 批准号:
2717407 - 财政年份:1998
- 资助金额:
$ 36.74万 - 项目类别:
ANTITUBERCULAR AGENTS FROM MEDICINAL PLANTS OF NIGERIA
来自尼日利亚药用植物的抗结核药物
- 批准号:
2385917 - 财政年份:1997
- 资助金额:
$ 36.74万 - 项目类别: